A Prospective, Single-Center, Single-Arm, Exploratory Study of 177Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.
Rapid radiopharmaceutical clearance limits the efficacy of peptide receptor radionuclide therapy (PRRT) for the treatment of advanced neuroendocrine tumors (NETs). In this prospective, single-center, single-arm, investigator-initiated trial, we evaluated the safety and efficacy of 177Lu-LNC1010-an optimized, long-actin...